Comparative Pharmacology
Head-to-head clinical analysis: ORA TESTRYL versus TESTOSTERONE ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORA TESTRYL versus TESTOSTERONE ENANTHATE.
ORA-TESTRYL vs TESTOSTERONE ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
Intramuscular injection: 50-100 mg every 2-4 weeks.
50-400 mg intramuscularly every 2-4 weeks
None Documented
None Documented
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Category C
Category D/X
Androgen
Androgen